Novel methods of antiepileptic drug delivery - Polymer-based implants

Advanced Drug Delivery Reviews

Volumn 64, Issue 10, 2012, Pages 953-964

  Halliday, Amy J ^a   Moulton, Simon E ^b   Wallace, Gordon G ^b   Cook, Mark J ^a  

^a BIONIC EAR INSTITUTE   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Biodegradable; Controlled release; Drug delivery; Epilepsy; Implants; Liposomes; Polymers

Indexed keywords

ANIMAL MODEL; ANTIEPILEPTIC DRUGS; BIODEGRADABLE; CONTROLLED RELEASE; EFFECTIVE DOSE; EPILEPSY; MATERIALS DEVELOPMENT; NEUROLOGICAL DISORDERS; NOVEL METHODS; POLYMER-BASED MATERIALS; POLYMERIC DEVICES; SIDE EFFECT;

DENTAL PROSTHESES; DRUG DELIVERY; LIPOSOMES; PATIENT TREATMENT; POLYMERS;

BIODEGRADABLE POLYMERS;

4 AMINOBUTYRIC ACID; ACETAZOLAMIDE; ADENOSINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHITOSAN; CILIARY NEUROTROPHIC FACTOR; CLONAZEPAM; DIAZEPAM; DIMER; ETHOSUXIMIDE; ETHYLENE VINYL ACETATE COPOLYMER; EUDRAGIT; FATTY ACID DIMER; GELUCIRE; MACROGOL; MK 80; MUSCIMOL; NORADRENALIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; POLY HYDROXYBUTYRATE VALERATE; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; PRIMIDONE; PROTIRELIN; SEBACIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ANTICONVULSANT THERAPY; BRAIN REGION; DIALYSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG IMPLANT; DRUG INDUSTRY; DRUG RELEASE; ELECTROSPINNING; EMULSION; EPILEPSY; EPILEPTIC FOCUS; EVAPORATION; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SEIZURE; SPRAY DRYING;

ANIMALS; ANTICONVULSANTS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EPILEPSY; HUMANS; POLYMERS;

EID: 84862901596     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.04.004     Document Type: Review

References (95)

1. Swarztrauber K., Dewar S., Engel J. Patient attitudes about treatments for intractable epilepsy. Epilepsy Behav. 2003, 4:19-25.
2. Shorvon S.D. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 1996, 37:S1-S3.
3. Sander J.W. The epidemiology of epilepsy revisited. Curr. Opin. Neurol. 2003, 16:165.
4. Löscher W., Schmidt D. New horizons in the development of antiepileptic drugs: the search for new targets. Epilepsy Res. 2004, 60:77-159.
5. Schmidt D., Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46:858-877.
6. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
7. Oby E., Janigro D. The blood-brain barrier and epilepsy. Epilepsia 2006, 47:1761-1774.
8. Stein A.G., Eder H.G., Blum D.E., Drachev A., Fisher R.S. An automated drug delivery system for focal epilepsy. Epilepsy Res. 2000, 39:103-114.
9. Fisher R.S., Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 2002, 16:579-593.
10. Misra A., Ganesh S., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci. 2003, 6:252-273.
11. Klitgaard H., Matagne A., Grimee R., Vanneste-Goemaere J., Margineanu D.G. Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure 2003, 12:92-100.
12. Eder H.G., Stein A., Fisher R.S. Interictal and ictal activity in the rat cobalt/pilocarpine model of epilepsy decreased by local perfusion of diazepam. Epilepsy Res. 1997, 29:17-24.
13. Brailowsky S., Silva-Barrat C., Ménini C., Riche D., Naquet R. Effects of localized, chronic GABA infusions into different cortical areas of the photosensitive baboon, Papio papio. Electroencephalogr. Clin. Neurophysiol. 1989, 72:147-156.
14. Serralta A., Barcia J.A., Ortiz P., Duran C., Hernandez M.E., Alos M. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model. Epilepsy Res. 2006, 15-26. (Epub 2006 Apr 17).
15. Barcia J.A., Rubio P., Alos M., Serralta A., Belda V. Anticonvulsant and neurotoxic effects of intracerebroventricular injection of phenytoin, phenobarbital and carbamazepine in an amygdala-kindling model of epilepsy in the rat. Epilepsy Res. 1999, 33:159-167.
16. Gonzalez-Darder J.M., Garcia-Teno M. Anticonvulsant effect of intraventricular antiepileptic drugs. Experimental study. Neurol. Res. 1995, 17:190-192.
17. Halliday A.J., Cook M.J. Polymer-based drug delivery devices for neurological disorders. CNS Neurol. Disord. Drug Targets 2009, 8:205-221.
18. Arinstein A., Zussman E. Electrospun polymer nanofibers: mechanical and thermodynamic perspectives. J. Polym. Sci., Part B: Polym. Phys. 2011, 49:691-707.
19. Yarin A.L. Coaxial electrospinning and emulsion electrospinning of core-shell fibers. Polym. Adv. Technol. 2011, 22:310-317.
20. He W., Yong T., Ma Z.W., Inai R., Teo W.E., Ramakrishna S. Biodegradable polymer nanofiber mesh to maintain functions of endothelial cells. Tissue Eng. 2006, 12:2457-2466.
21. Suganya S., Senthil Ram T., Lakshmi B.S., Giridev V.R. Herbal drug incorporated antibacterial nanofibrous mat fabricated by electrospinning: an excellent matrix for wound dressings. J. Appl. Polym. Sci. 2011, 121:2893-2899.
22. Russo G., Lamberti G. Electrospinning of drug-loaded polymer systems: preparation and drug release. J. Appl. Polym. Sci. 2011, 122:3551-3556.
23. Park Y., Kang E., Kwon O.J., Hwang T., Park H., Lee J.M., Kim J.H., Yun C.O. Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy. J. Control. Release 2010, 148:75-82.
24. Wang C., Yan K.-W., Lin Y.-D., Hsieh P.C.H. Biodegradable core/shell fibers by coaxial electrospinning: processing, fiber characterization, and its application in sustained drug release. Macromolecules 2010, 43:6389-6397.
25. Tiwari S.K., Tzezana R., Zussman E., Venkatraman S.S. Optimizing partition-controlled drug release from electrospun core-shell fibers. Int. J. Pharm. 2010, 392:209-217.
26. Kenawy E., Bowlin G., Mansfield K., Layman J., Simpson D., Sanders E., Wnek G. Release of tetracycline hydrochloride from electrospun poly (ethylene-co-vinylacetate), poly (lactic acid), and a blend. J. Control. Release 2002, 81:57-64.
27. Zong X., Kim K., Fang D., Ran S., Hsiao B., Chu B. Structure and process relationship of electrospun bioabsorbable nanofiber membranes. Polymer 2002, 43:4403-4412.
28. Zeng J., Xu X., Chen X., Liang Q., Bian X., Yang L., Jing X. Biodegradable electrospun fibers for drug delivery. J. Control. Release 2003, 92:227-231.
29. Tiwari S., Tzezana R., Zussman E., Venkatraman S. Optimizing partition-controlled drug release from electrospun core-shell fibers. Int. J. Pharm. 2010, 392(1-2):209-217.
30. Chen M., Dong M., Havelund R., Regina V.R., Meyer R.L., Besenbacher F., Kingshott P. Thermo-responsive core-sheath electrospun nanofibers from poly (n-isopropylacrylamide)/polycaprolactone blends. Chem. Mater. 2010, 22:4214-4221.
31. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 2002, 54:107-117.
32. Kou J., Emmett C., Shen P., Aswani S., Iwamoto T., Vaghefi F., Cain G., Sanders L. Bioerosion and biocompatibility of poly (d, l-lactic-co-glycolic acid) implants in brain. J. Control. Release. 1997, 43:123-130.
33. Viitanen P., Suokas E., Törmälä P., Ashammakhi N. Release of diclofenac sodium from polylactide-co-glycolide 80/20 rods. J. Mater. Sci. Mater. Med. 2006, 17:1267-1274.
34. Wang L., Wang J., Lin X., Tang X. Preparation and in vitro evaluation of gliclazide sustained-release matrix pellets: formulation and storage stability. Drug Dev. Ind. Pharm. 2010, 36:814-822.
35. Younes B., Fotheringham A. Factorial optimization of the effects of melt-spinning conditions on biodegradable as-spun aliphatic-aromatic copolyester fibers. III. Diameter, tensile properties, and thermal shrinkage. J. Appl. Polym. Sci. 2011, 122:1434-1449.
36. Abu-Diak O.A., Jones D.S., Andrews G.P. An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations. Mol. Pharm. 2011, 8:1362-1371.
37. Boland T., Xu T., Damon B., Cui X. Application of inkjet printing to tissue engineering. Biotechnol. J. 2006, 1:910-917.
38. Zhang C., Zhao K., Hu T., Cui X., Brown N., Boland T. Loading dependent swelling and release properties of novel biodegradable, elastic and environmental stimuli-sensitive polyurethanes. J. Control. Release 2008, 131:128-136.
39. Rattanakit P., Moulton S.E., Santiago K.S., Liawruangrath S., Wallace G.G. Extrusion printed polymer structures: A facile and versatile approach to tailored drug delivery platforms. Int. J. Pharm. 2012, 422:254-263.
40. Goldring S., Gregorie E.M. Surgical management of epilepsy using epidural recordings to localize the seizure focus. J. Neurosurg. 1984, 60:457-466.
41. Sezer A.D., Akbuga J. The design of biodegradable ofloxacin-based core-shell microspheres: influence of the formulation parameters on in vitro characterization. Pharm. Dev. Technol. 2010, 1-7.
42. Gregory A., Stenzel M.H. The use of reversible addition fragmentation chain transfer polymerization for drug delivery systems. Expert Opin. Drug Deliv. 2011, 8:237-269.
43. Su X., Fricke J., Kavanagh D.G., Irvine D.J. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol. Pharm. 2011, 8:774-787.
44. Xiong S., Zhao X., Heng B.C., Ng K.W., Loo J.S.-C. Cellular uptake of poly-(d, l-lactide-co-glycolide) (PLGA) nanoparticles synthesized through solvent emulsion evaporation and nanoprecipitation method. Biotechnol. J. 2011, 6:501-508.
45. Liu Y., Deng X. Influences of preparation conditions on particle size and DNA-loading efficiency for poly (-lactic acid-polyethylene glycol) microspheres entrapping free DNA. J. Control. Release 2002, 83:147-155.
46. Eley J., Mathew P. Preparation and release characteristics of insulin and insulin-like growth factor-one from polymer nanoparticles. J. Microencapsul. 2007, 24:225-234.
47. Lee J., Oh Y.J., Lee S.K., Lee K.Y. Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery. J. Control. Release 2010, 146:61-67.
48. Chan H.-K., Kwok P.C.L. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 2011, 63:406-416.
49. Sivadas N., O'Rourke D., Tobin A., Buckley V., Ramtoola Z., Kelly J., Hickey A., Cryan S. A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int. J. Pharm. 2008, 358:159-167.
50. Zhang J., Zheng Z., Gao Y., Zhang Y. Spray-dried oil-in-water emulsion to improve the intestinal absorption and oral bioavailability of ZLR-8, a nitric oxide-releasing derivative of diclofenac. J. Pharm. Pharmacol. 2011, 63:1531-1538.
51. Learoyd T.P., Burrows J.L., French E., Seville P.C. Sustained delivery of salbutamol and beclometasone from spray-dried double emulsions. J. Microencapsul. 2010, 27:162-170.
52. Amsden B., Goosen M. An examination of factors affecting the size, distribution and release characteristics of polymer microbeads made using electrostatics. J. Control. Release 1997, 43:183-196.
53. Loscertales I., Barrero A., Guerrero I., Cortijo R., Marquez M., Ganan-Calvo A. Micro/nano encapsulation via electrified coaxial liquid jets. Science 2002, 295:1695.
54. Xu Y., Hanna M. Electrospray encapsulation of water-soluble protein with polylactide: effects of formulations on morphology, encapsulation efficiency and release profile of particles. Int. J. Pharm. 2006, 320:30-36.
55. Dalwadi G., Sunderland B. Comparison and validation of drug loading parameters of PEGylated nanoparticles purified by a diafiltration centrifugal device and tangential flow filtration. Drug Dev. Ind. Pharm. 2008, 34:1331-1342.
56. Kokaia M., Aebischer P., Elmer E., Bengzon J., Kalen P., Kokaia Z., Lindvall O. Seizure suppression in kindling epilepsy by intracerebral implants of GABA - but not by noradrenaline-releasing polymer matrices. Exp. Brain Res. 1994, 100:385-394.
57. Boison D., Scheurer L., Tseng J.L., Aebischer P., Mohler H. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp. Neurol. 1999, 160:164-174.
58. Haik-Creguer K.L., Dunbar G.L., Sabel B.A., Schroeder U. Small drug sample fabrication of controlled release polymers using the microextrusion method. J. Neurosci. Methods 1998, 80:37-40.
59. Smith A.L., Cordery P.M., Thompson I.D. Manufacture and release characteristics of Elvax polymers containing glutamate receptor antagonists. J. Neurosci. Methods 1995, 60:211-217.
60. Tamargo R.J., Rossell L.A., Kossoff E.H., Tyler B.M., Ewend M.G., Aryanpur J.J. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res. 2002, 48:145-155.
61. Kubek M.J., Liang D., Byrd K.E., Domb A.J. Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Brain Res. 1998, 809:189-197.
62. Cho C.S., Han S.Y., Ha J.H., Kim S.H., Lim D.Y. Clonazepam release from bioerodible hydrogels based on semi-interpenetrating polymer networks composed of poly(epsilon-caprolactone) and poly(ethylene glycol) macromer. Int. J. Pharm. 1999, 181:235-242.
63. Pritchard E., Szybala C., Boison D., Kaplan D. Silk fibroin encapsulated powder reservoirs for sustained release of adenosine. J. Control. Release 2010, 144:159-167.
64. Wilz A., Pritchard E.M., Li T., Lan J.Q., Kaplan D.L., Boison D. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials 2008, 29:3609-3616. (Epub 2008 Jun 2).
65. Szybala C., Pritchard E., Lusardi T., Li T., Wilz A., Kaplan D., Boison D. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp. Neurol. 2009, 219:126-135.
66. Barakat N.S., Radwan M.A. In vitro performance of carbamazepine loaded to various molecular weights of poly (d, l-lactide-co-glycolide). Drug Deliv. 2006, 13:9-18.
67. Barakat N.S., Yassin A.E. In vitro characterization of carbamazepine-loaded precifac lipospheres. Drug Deliv. 2006, 13:95-104.
68. Dong W.Y., Maincent P., Bodmeier R. In vitro and in vivo evaluation of carbamazepine-loaded enteric microparticles. Int. J. Pharm. 2007, 331:84-92.
69. Filipovic-Grcic J., Perissutti B., Moneghini M., Voinovich D., Martinac A., Jalsenjak I. Spray-dried carbamazepine-loaded chitosan and HPMC microspheres: preparation and characterisation. J. Pharm. Pharmacol. 2003, 55:921-931.
70. Fresta M., Cavallaro G., Giammona G., Wehrli E., Puglisi G. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials 1996, 17:751-758.
71. Gavini E., Hegge A.B., Rassu G., Sanna V., Testa C., Pirisino G., Karlsen J., Giunchedi P. Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int. J. Pharm. 2006, 307:9-15.
72. Passerini N., Perissutti B., Moneghini M., Voinovich D., Albertini B., Cavallari C., Rodriguez L. Characterization of carbamazepine-Gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J. Pharm. Sci. 2002, 91:699-707.
73. Patterson J.E., James M.B., Forster A.H., Rades T. Melt extrusion and spray drying of carbamazepine and dipyridamole with polyvinylpyrrolidone/vinyl acetate copolymers. Drug Dev. Ind. Pharm. 2008, 34:95-106.
74. Duarte A.R., Roy C., Vega-Gonzalez A., Duarte C.M., Subra-Paternault P. Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int. J. Pharm. 2007, 332:132-139. (Epub 2006 Sep 29).
75. Haznedar S., Dortunc B. Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide. Int. J. Pharm. 2004, 269:131-140.
76. Montanari L., Cilurzo F., Valvo L., Faucitano A., Buttafava A., Groppo A., Genta I., Conti B. Gamma irradiation effects on stability of poly(lactide-co-glycolide) microspheres containing clonazepam. J. Control. Release 2001, 75:317-330.
77. Rane Y.M., Mashru R.C., Sankalia M.G., Sutariya V.B., Shah P.P. Investigations on factors affecting chitosan for dissolution enhancement of oxcarbazepine by spray dried microcrystal formulation with an experimental design approach. Drug Dev. Ind. Pharm. 2007, 33:1008-1023.
78. Berrabah M., Andre D., Prevot F., Orecchioni A.M., Lafont O. GC-MS determination of phenobarbitone entrapped in poly-epsilon-caprolactone nanocapsules. J. Pharm. Biomed. Anal. 1994, 12:373-378.
79. Giannola L.I., De Caro V., Di Stefano V., Rizzo M.C. In vitro evaluation of cumulative release of valproic acid and vitamin E from hexadecanol microspheres. Part 2: antiepileptic agents. Pharmazie 1993, 48:917-920.
80. Ferranti V., Marchais H., Chabenat C., Orecchioni A.M., Lafont O. Primidone-loaded poly-epsilon-caprolactone nanocapsules: incorporation efficiency and in vitro release profiles. Int. J. Pharm. 1999, 193:107-111.
81. Kohane D., Holmes G., Chau Y., Zurakowski D., Langer R., Cha B. Effectiveness of muscimol containing microparticles against pilocarpine induced focal seizures. Epilepsia 2002, 43:1462-1468.
82. Benelli P., Conti B., Genta I., Costantini M., Montanari L. Clonazepam microencapsulation in poly-d, l-lactide-co-glycolide microspheres. J. Microencapsul. 1998, 15:431-443.
83. Barichello J., Morishita M., Takayama K., Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev. Ind. Pharm. 1999, 25:471-476.
84. Nkansah M.K., Tzeng S.Y., Holdt A.M., Lavik E.B. Poly(lactic-co-glycolic acid) nanospheres and microspheres for short- and long-term delivery of bioactive ciliary neurotrophic factor. Biotechnol. Bioeng. 2008, 100:1010-1019.
85. Bodmeier R., McGinity J. The preparation and evaluation of drug-containing poly (dl-lactide) microspheres formed by the solvent evaporation method. Pharm. Res. 1987, 4:465-471.
86. Giunchedi P., Conti B., Scalia S., Conte U. In vitro degradation study of polyester microspheres by a new HPLC method for monomer release determination. J. Control. Release. 1998, 56:53-62.
87. Chen J., Davis S.S. The release of diazepam from poly(hydroxybutyrate-hydroxyvalerate) microspheres. J. Microencapsul. 2002, 19:191-201.
88. Li Z., Li Q., Simon S., Guven N., Borges K., Youan B.B. Formulation of spray-dried phenytoin loaded poly(epsilon-caprolactone) microcarrier intended for brain delivery to treat epilepsy. J. Pharm. Sci. 2007, 96:1018-1030.
89. Jeong Y.I., Cheon J.B., Kim S.H., Nah J.W., Lee Y.M., Sung Y.K., Akaike T., Cho C.S. Clonazepam release from core-shell type nanoparticles in vitro. J. Control. Release 1998, 51:169-178.
90. Ryu J., Jeong Y.I., Kim I.S., Lee J.H., Nah J.W., Kim S.H. Clonazepam release from core-shell type nanoparticles of poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) triblock copolymers. Int. J. Pharm. 2000, 200:231-242.
91. Nah J.W., Paek Y.W., Jeong Y.I., Kim D.W., Cho C.S., Kim S.H., Kim M.Y. Clonazepam release from poly(dl-lactide-co-glycolide) nanoparticles prepared by dialysis method. Arch. Pharm. Res. 1998, 21:418-422.
92. Adams D., Joyce G., Richardson V., Ryman B.E., Wisniewski H. Liposome toxicity in the mouse central nervous system. J. Neurol. Sci. 1977, 31:173-179.
93. Boggs J.G., Nowack W.J., Drinkard C. Analysis of the 'honeymoon effect' in adult epilepsy patients. Epilepsia 2000, 41. suppl. 7, p 222.
94. Güttinger M., Fedele D., Koch P., Padrun V., Pralong W., Brüstle O., Boison D. Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants. Epilepsia 2005, 46:1162-1169.
95. Li T., Steinbeck J., Lusardi T., Koch P., Lan J., Wilz A., Segschneider M., Simon R., Brustle O., Boison D. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 2007, 130:1276.